Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
Interventions: Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride, Lurbinectedin; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Lenvatinib, Pembrolizumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Labor Long
Interventions: Oxytocin (Low dose), Oxytocin (High dose); Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions: EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sickle Cell Disease, Cerebral Stroke
Interventions: Carbon Dioxide; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hematological Malignancies
Interventions: Regimen A, Regimen B, Regimen C; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Year to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Head and Neck Cancer
Interventions: Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 10
States / cities: New Haven, Connecticut • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma/Leukemia
Interventions: Clofarabine, Mitoxantrone; Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 30 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Valhalla, New York • Charlotte, North Carolina

Conditions: Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
Interventions: ULTRAFORMER MPT PLUS, Ulthera System; Device
Lead sponsor: CLASSYS Inc.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Charlotte, North Carolina • Wilmington, North Carolina + 2 more

Conditions: Tumor Lysis Syndrome
Interventions: As Needed Rasburicase, Fixed Dose Rasburicase; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Insufficiency
Interventions: Pulmonary Function Testing & esophageal pressure monitoring, Pulmonary function testing and esophageal pressure; Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 2 Days to 6 Months
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Prostate Cancer
Interventions: Drug: 99mTc-MIP-1404; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Duarte, California • Rochester, Minnesota • New York, New York + 7 more

Conditions: Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Indium In-111 Ibritumomab Tiuxetan, Mycophenolate Mofetil, Pharmacological Study, Rituximab, Total-Body Irradiation, Yttrium Y-90 Ibritumomab Tiuxetan, Fludarabine; Procedure · Drug · Radiation + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Covid19, Critical Illness, High Intensity Interval Training, ICU, Intensive Care Units, Fitness Trackers
Interventions: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT), Comparator; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Nashville, Tennessee

Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Poorly Differentiated Carcinoma, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer
Interventions: trastuzumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Hypoxemic Respiratory Failure
Interventions: HFNC only, HFNC + CNEP10, HFNC + CNEP20, HFNC + CNEP30; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Brooklyn, New York • New York, New York

Conditions: Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
Interventions: LITT + Pembrolizumab; Combination Product
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Metastatic Colorectal Cancer
Interventions: Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Sacramento, California • Denver, Colorado + 6 more

Conditions: Primary Immunodeficiency Disease
Interventions: NewGam; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Irvine, California • Centennial, Colorado • Chicago, Illinois + 3 more

Conditions: Cataracts
Interventions: Acrysof IQ (SN60WF) IOL; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Coronary Artery Disease
Interventions: Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT; Combination Product
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: East Syracuse, New York • New York, New York • Anderson, South Carolina + 1 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Clofarabine, Cytarabine, Decitabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Fosaprepitant; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: AML
Interventions: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose, Ruxolitinib, Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 20
States / cities: Duarte, California • La Jolla, California • San Francisco, California + 16 more

Search by objective public record fields.

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography

Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)

Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

REmotely Monitored, Mobile Health-Supported High Intensity Interval Training After COVID-19 Critical Illness (REMM-HIIT-COVID-19)

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure

LITT and Pembrolizumab in Recurrent Brain Metastasis

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

An Assessment of Residual Spherical Aberration, Postoperative Total High Order Aberrations, and Functional Vision Correlation Following Intraocular Lens (IOL) Implantation

A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)